GLP-1 Obesity Drug Pipeline: 15+ Compounds Including Multi-Hormone Combinations in Development
Over 15 GLP-1-based compounds are in clinical development for obesity, ranging from pure GLP-1 agonists (semaglutide) to dual and triple hormone combinations targeting GLP-1 plus glucagon, GIP, and/or amylin receptors.
Quick Facts
What This Study Found
15+ GLP-1-based compounds in clinical obesity development: mono-GLP-1 (semaglutide, PF-0688296, glutazumab), dual (tirzepatide, cotadutide, efinopegdutide, AMG 133), and multi-receptor (CagriSema, HM15211). Semaglutide positioned as the clinical benchmark.
Key Numbers
>15 compounds; semaglutide benchmark; tirzepatide GLP-1/GIP; cotadutide GLP-1/glucagon; cagrilintide+semaglutide; 1.1B projected obese by 2030
How They Did This
Expert review of GLP-1 receptor agonist-based compounds in clinical development for obesity treatment, covering mechanisms, development stages, and clinical pipeline.
Why This Research Matters
The obesity drug market is undergoing a revolution. Understanding the pipeline helps patients and clinicians anticipate future treatment options that may produce even greater weight loss than current drugs.
The Bigger Picture
The GLP-1 obesity drug space is the most active pharmaceutical pipeline in history. Multi-receptor approaches are expected to achieve weight loss approaching surgical levels, potentially transforming obesity from a lifelong condition to a treatable disease.
What This Study Doesn't Tell Us
Pipeline review — many compounds are in early clinical development and may not reach market. Clinical efficacy varies widely between compounds. Long-term safety of multi-hormone combinations unknown.
Questions This Raises
- ?Which multi-hormone combination will produce the greatest weight loss with acceptable side effects?
- ?Will any of these compounds achieve surgical-level weight loss (>25%)?
- ?How will pricing and access affect the obesity treatment landscape?
Trust & Context
- Key Stat:
- 15+ compounds in pipeline The GLP-1 obesity pipeline includes over 15 compounds from pure GLP-1 to multi-receptor drugs, with semaglutide 2.4 mg as the benchmark for comparison
- Evidence Grade:
- Not applicable (pipeline review). Based on published clinical trial data and development-stage information for each compound.
- Study Age:
- Published 2021. Since then, tirzepatide has been approved for obesity and several pipeline compounds have advanced or been discontinued.
- Original Title:
- Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity.
- Published In:
- Expert opinion on emerging drugs, 26(3), 231-243 (2021)
- Authors:
- Jepsen, Mathies M, Christensen, Mikkel B(3)
- Database ID:
- RPEP-05467
Evidence Hierarchy
Frequently Asked Questions
What new weight loss drugs are coming?
Beyond currently available semaglutide and tirzepatide, multi-hormone drugs targeting GLP-1 plus glucagon, amylin, or other hormones are in clinical trials. CagriSema (semaglutide + amylin analogue) and various triple-agonists may produce even greater weight loss.
Will future GLP-1 drugs be better than Ozempic?
Likely yes. Multi-receptor drugs that target GLP-1 plus additional appetite/metabolic hormones have shown greater weight loss in early trials. Tirzepatide already outperforms semaglutide, and newer combinations may go further.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05467APA
Jepsen, Mathies M; Christensen, Mikkel B. (2021). Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity.. Expert opinion on emerging drugs, 26(3), 231-243. https://doi.org/10.1080/14728214.2021.1947240
MLA
Jepsen, Mathies M, et al. "Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity.." Expert opinion on emerging drugs, 2021. https://doi.org/10.1080/14728214.2021.1947240
RethinkPeptides
RethinkPeptides Research Database. "Emerging glucagon-like peptide 1 receptor agonists for the t..." RPEP-05467. Retrieved from https://rethinkpeptides.com/research/jepsen-2021-emerging-glucagonlike-peptide-1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.